Analysts Set MEDNAX Inc (MD) Price Target at $55.58

Shares of MEDNAX Inc (NYSE:MD) have been assigned a consensus recommendation of “Hold” from the sixteen analysts that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $55.58.

Several equities research analysts have recently commented on the stock. Citigroup dropped their target price on shares of MEDNAX from $57.00 to $50.00 and set a “neutral” rating for the company in a research report on Friday, May 4th. BMO Capital Markets increased their price target on shares of MEDNAX from $46.00 to $58.00 and gave the stock a “market perform” rating in a research note on Monday, February 12th. Zacks Investment Research lowered shares of MEDNAX from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 21st. Credit Suisse Group decreased their price target on shares of MEDNAX to $57.00 and set a “neutral” rating for the company in a research note on Monday, May 7th. Finally, TheStreet upgraded shares of MEDNAX from a “c+” rating to a “b” rating in a research note on Monday, March 12th.

Shares of NYSE:MD traded down $0.50 on Thursday, hitting $46.42. The company had a trading volume of 10,501 shares, compared to its average volume of 576,498. MEDNAX has a 1 year low of $40.56 and a 1 year high of $63.04. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.63. The stock has a market cap of $4.38 billion, a price-to-earnings ratio of 14.94, a P/E/G ratio of 1.18 and a beta of 0.24.

MEDNAX (NYSE:MD) last posted its earnings results on Monday, April 30th. The company reported $0.89 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.82 by $0.07. MEDNAX had a net margin of 9.34% and a return on equity of 10.13%. The firm had revenue of $901.90 million during the quarter, compared to analysts’ expectations of $903.75 million. During the same period last year, the company posted $0.75 EPS. The company’s quarterly revenue was up 7.9% compared to the same quarter last year. equities analysts forecast that MEDNAX will post 3.94 EPS for the current fiscal year.

In other MEDNAX news, COO Joseph M. Calabro sold 22,186 shares of the firm’s stock in a transaction dated Friday, June 1st. The shares were sold at an average price of $45.20, for a total transaction of $1,002,807.20. Following the completion of the sale, the chief operating officer now directly owns 332,747 shares in the company, valued at approximately $15,040,164.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider David A. Clark sold 11,607 shares of the firm’s stock in a transaction dated Friday, June 1st. The shares were sold at an average price of $45.15, for a total transaction of $524,056.05. Following the sale, the insider now owns 32,845 shares of the company’s stock, valued at $1,482,951.75. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 36,793 shares of company stock valued at $1,666,153. 2.70% of the stock is owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the business. GHP Investment Advisors Inc. boosted its holdings in shares of MEDNAX by 13.8% during the 4th quarter. GHP Investment Advisors Inc. now owns 7,735 shares of the company’s stock valued at $413,000 after acquiring an additional 940 shares during the last quarter. Amalgamated Bank boosted its holdings in shares of MEDNAX by 5.9% during the 4th quarter. Amalgamated Bank now owns 18,448 shares of the company’s stock valued at $986,000 after acquiring an additional 1,035 shares during the last quarter. LPL Financial LLC boosted its holdings in shares of MEDNAX by 8.9% during the 1st quarter. LPL Financial LLC now owns 15,153 shares of the company’s stock valued at $843,000 after acquiring an additional 1,233 shares during the last quarter. Macquarie Group Ltd. boosted its holdings in shares of MEDNAX by 36.1% during the 4th quarter. Macquarie Group Ltd. now owns 4,900 shares of the company’s stock valued at $262,000 after acquiring an additional 1,300 shares during the last quarter. Finally, Commerce Bank boosted its holdings in shares of MEDNAX by 9.6% during the 4th quarter. Commerce Bank now owns 15,868 shares of the company’s stock valued at $848,000 after acquiring an additional 1,393 shares during the last quarter. Institutional investors and hedge funds own 97.39% of the company’s stock.

About MEDNAX

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.

Analyst Recommendations for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply